Evolocumab reduces cardiac events in high-risk diabetic patients
Evolocumab: A New Era in Proactive Heart Disease Prevention? A groundbreaking analysis from the VESALIUS-CV trial, presented at the American College of Cardiology’s Annual Scientific Session, suggests a potential shift in how we approach heart disease prevention. The study reveals that evolocumab, a PCSK9 inhibitor, significantly reduced the risk of major cardiovascular events – by … Read more